SCHEMBL4249037

SCHEMBL4249037

CCCCCCOC(=O)/C=C(\Oc1ccccc1[N+](=O)[O-])C(=O)OCCCCCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 3/20 0.44
KMT2A Q03164 3/20 0.44
ESR1 P03372 1/20 0.44
POLB P06746 1/20 0.41
LMNA P02545 3/20 0.40
ALDH1A1 P00352 3/20 0.40
TSHR P16473 2/20 0.40
MAPT P10636 2/20 0.40
CYP3A4 P08684 2/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 1/20 0.40
RECQL P46063 1/20 0.40
NR1I2 O75469 1/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
OPRK1 P41145 1/20 0.40
HTR2B P41595 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249042 1.00 L3MBTL1 (0.47) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4252634 1.00 L3MBTL1 (0.47) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4251552 0.96 RAB9A (0.46) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4251557 0.96 RAB9A (0.46) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4254610 0.96 RAB9A (0.46) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4249053 0.91 RAB9A (0.47) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4252616 0.91 RAB9A (0.47) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4249056 0.91 RAB9A (0.47) L3MBTL1GAAHPGDRAB9AKMT2A
SCHEMBL4247741 0.84 RAB9A (0.58) L3MBTL1RAB9AKMT2APOLBLMNA
SCHEMBL4247745 0.84 RAB9A (0.58) L3MBTL1RAB9AKMT2APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2105431-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-2105432-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-1867626-A2 Process for producing chromone compound Sumitomo Chemical Company, Limited (JP) 2007-12-19 EP disclosed
US-20060217565-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-28 US disclosed
US-7094914-B2 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-22 US disclosed
US-20050085664-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LMITED (JP) 2005-04-21 US disclosed
EP-1479667-A1 PROCESS FOR PRODUCING CHROMONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085664-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL L3MBTL1 3519/4885GAA 2812/4885HPGD 775/4885
US-20060217565-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL L3MBTL1 3519/4885GAA 2812/4885HPGD 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.